Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(3.61)
# 798
Out of 4,876 analysts
15
Total ratings
66.67%
Success rate
4.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Initiates: Overweight | $44 | $22.29 | +97.40% | 1 | Jun 26, 2025 | |
| ITOS iTeos Therapeutics | Downgrades: Equal-Weight | $13 → $12 | $10.02 | +19.76% | 6 | May 28, 2025 | |
| BCAX Bicara Therapeutics | Upgrades: Equal-Weight | $8 | $8.81 | -9.19% | 2 | May 23, 2025 | |
| MRUS Merus | Maintains: Overweight | $91 → $89 | $53.18 | +67.36% | 1 | May 8, 2025 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $29 → $26 | $8.50 | +205.88% | 2 | May 7, 2025 | |
| XNCR Xencor | Maintains: Overweight | $37 → $33 | $8.40 | +292.86% | 2 | Feb 28, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Initiates: Overweight | $34 | $28.49 | +19.34% | 1 | May 3, 2024 |
IDEAYA Biosciences
Jun 26, 2025
Initiates: Overweight
Price Target: $44
Current: $22.29
Upside: +97.40%
iTeos Therapeutics
May 28, 2025
Downgrades: Equal-Weight
Price Target: $13 → $12
Current: $10.02
Upside: +19.76%
Bicara Therapeutics
May 23, 2025
Upgrades: Equal-Weight
Price Target: $8
Current: $8.81
Upside: -9.19%
Merus
May 8, 2025
Maintains: Overweight
Price Target: $91 → $89
Current: $53.18
Upside: +67.36%
Arcus Biosciences
May 7, 2025
Maintains: Overweight
Price Target: $29 → $26
Current: $8.50
Upside: +205.88%
Xencor
Feb 28, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $8.40
Upside: +292.86%
Kiniksa Pharmaceuticals International,
May 3, 2024
Initiates: Overweight
Price Target: $34
Current: $28.49
Upside: +19.34%